Clinical trial • Phase III • Respiratory

buloxibutid for Idiopathic pulmonary fibrosis

Phase III trial of buloxibutid for Idiopathic pulmonary fibrosis. Randomised, open-label, none/not specified-controlled. 24 participants.

Overview

Trial Therapeutic Area: Respiratory
Trial Disease: Idiopathic pulmonary fibrosis
Trial Stage: Phase III

Key dates

Initial CTIS Submission Date: 27-03-2026
First CTIS Authorization Date: 28-04-2026

Trial design

Randomised, open-label, none/not specified-controlled Phase III trial across 1 site in Sweden.

Randomised: Yes
Open Label: Yes
Comparator: None/Not specified
Target Sample Size: 24
Trial Duration For Participant: 64

Eligibility

Recruits 24 Vulnerable population selected (isVulnerablePopulationSelected=true) - no further consent or assent details provided in the record..

Vulnerable Population: Vulnerable population selected (isVulnerablePopulationSelected=true) - no further consent or assent details provided in the record.

Recruitment

Planned Sample Size: 24
Recruitment Window Months: 2
Consent Approach: No informed consent or assent process details provided in the record.

Geography

Total Number Of Sites: 1
Total Number Of Participants: 24

Sweden

Earliest CTIS Part Ii Submission Date: 21-04-2026
Latest Decision Or Authorization Date: 28-04-2026
Processing Time Days: 7
Number Of Sites: 1
Number Of Participants: 24

Sites

Site Name: Dag Hammarskjolds Vag 10b, Uppsala Domkyrkofors.
Department Name: CTC Clinical Trial Consultants AB
Contact Person Name: Johan Nilsson
Contact Person Email: johan.nilsson@ctc-ab.se

Sponsor

Primary sponsor

Full Name: Vicore Pharma AB
Organisation Type: Pharmaceutical company
Country Of Registered Address: Sweden

Investigational products

Investigational Product Name: buloxibutid
Active Substance: buloxibutid

Combination Treatment: Yes

Related trials

Other published trials that may interest you.